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Abstract
The cancer-testis (CT) family of antigens is expressed in a variety of malignant neoplasms. In most cases, no CT antigen is
found in normal tissues, except in testis, making them ideal targets for cancer immunotherapy. A comprehensive analysis of
CT antigen expression has not yet been reported in prostate cancer. MAGE-C2/CT-10 is a novel CT antigen. The objective of
this study was to analyze extent and prognostic significance of MAGE-C2/CT10 protein expression in prostate cancer. 348
prostate carcinomas from consecutive radical prostatectomies, 29 castration-refractory prostate cancer, 46 metastases, and
45 benign hyperplasias were immunohistochemically analyzed for MAGE-C2/CT10 expression using tissue microarrays.
Nuclear MAGE-C2/CT10 expression was identified in only 3.3% primary prostate carcinomas. MAGE-C2/CT10 protein
expression was significantly more frequent in metastatic (16.3% positivity) and castration-resistant prostate cancer (17%
positivity; p,0.001). Nuclear MAGE-C2/CT10 expression was identified as predictor of biochemical recurrence after radical
prostatectomy (p = 0.015), which was independent of preoperative PSA, Gleason score, tumor stage, and surgical margin
status in multivariate analysis (p,0.05). MAGE-C2/CT10 expression in prostate cancer correlates with the degree of
malignancy and indicates a higher risk for biochemical recurrence after radical prostatectomy. Further, the results suggest
MAGE-C2/CT10 as a potential target for adjuvant and palliative immunotherapy in patients with prostate cancer.
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Introduction
When prostate cancer is localized in the prostate, the treatment
of choice is prostatectomy or irradiation. However, when the
tumor relapses or is already metastatic at diagnosis, therapy is
problematic. Castration has been the main treatment option for
unconfined disease for more than 50 years. However, patients
frequently progress after endocrine treatment [1]. Occurrence of
castration resistance is associated with poor prognosis and only
palliative therapy is available in such advanced tumor stages.
Immunotherapy targeting cancer-testis (CT) antigens are promis-
ing new treatment modalities for advanced lung cancer, ovarian
cancer and melanoma patients [2],[3],[4],[5],[6],[7],[8],[9] but
CT antigens, except NY-ESO-1 [10], haven’t been employed as
vaccine targets for prostate cancer.
In most cases, CT antigens are only expressed in germ cells
of the human testis. To date, more than 100 CT antigens have
been identified, which belong to at least 44 distinct families. CT
antigens mapping to chromosome X are referred to as CT-X
antigens and distinguished from Non-X CT antigens located on
other chromosomes [11]. The expression of CT-X antigens varies
greatly between different tumor types and are more prevalent in
higher grade and advanced stage tumors [12],[13],[14],[15]. They
are most frequently expressed in melanomas [16], bladder [17],
[18], lung [12], ovarian [19], and hepatocellular carcinomas [20],
and are uncommon in renal cell carcinoma [21], colon cancer
[22], and hematological malignancies [23].
Interestingly, a member of the CT antigens,MAGE-A11 appears
to directly contribute to the development of androgen independent
prostate tumor growth by stimulating the activity of the androgen
receptor [24]. MAGE-A11 expression is regulated by DNA methy-
lation status: in castration-recurrent prostate tumors,MAGE-A11 is
upregulated, correlating with hypomethylation of discrete CpG
sites adjacent to the transcriptional start site of the gene, by
contrast, the methylation status of other regions of the MAGE-A11
promoter CpG island does not correlate with gene expression [24].
Furthermore, treatment of prostate cells with decitabine causes
upregulation of MAGE-A11 expression [24],[25].
Studies analysing mRNA expression [26],[27],[28],[29],[30]
and immunohistochemical analyses [31],[32],[33] of several CT
antigens have been performed. There is evolving evidence that
NY-ESO-1 expression in the tumor changes from negative to
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positive during the progression of disease [34]. In prostate can-
cer, which is known to be a relatively slow progressing disease,
expression ranges stage dependant from 5% to 30% [29],[31].
Recently, an antibody against MAGE-C2/CT-10, a novel CT
antigen has been generated [35]. The MAGE-C2/CT-10 gene
shows significant homology with the MAGE-C1/CT-7 gene and
both genes map in close proximity to chromosome Xq27.13.
MAGE-C2/CT-10 was originally identified in a melanoma cell
line. Until now, MAGE-C2/CT10 mRNA expression in prostate
cancer was analysed in few prostate samples, only: In a study by
Prikler et al., 12 castration-resistent and eight hormone sensitive
tumors were CT10 negative. Furthermore, Lucas et al. found one
of ten prostate cancer tissues to be CT10 positive [28],[30].
We have reported MAGE-C2/CT-10 in a large proportion of
hepatocellular carcinoma (HCC) [20]. While testing the MAGE-
C2/CT-10 antibody in a multi-tumor tissue microarray, we
identified MAGE-C2/CT10 protein expression in single PCa
cases. Based on this observation, we performed a comprehensive
tissue microarray-based analysis of PCa. We demonstrate that
protein expression of MAGE-C2/CT10 is found in a substantial
subset of prostate cancer, mainly metastatic and castration resis-
tant primary tumors. We further show that MAGE-C2/CT10
expression was identified as predictor of biochemical recurrence
after radical prostatectomy, independent of known risk factors.
Materials and Methods
Prostate tissue microarrays
A total of 468 formalin-fixed, paraffin-embedded prostate
tissues was retrieved from the archives of the Institute of Surgical
Pathology, University Zurich, Switzerland and a tissue microarray
(TMA) was constructed as described previously [36]. The TMA
included a series of 348 consecutive (non-selected) radical pros-
tatectomy specimens with prostate cancer, 29 castration resistent
prostate cancer samples, 18 lymph node metastases, 28 distant
metastases (bone, lung, urinary bladder) and 45 benign prostatic
hyperplasia samples. H&E-stained slides of all specimens were
re-evaluated by experienced pathologists (P.J.W., H.M.) to identify
representative areas for TMA construction. Tumor stage and
Gleason score of the cohort were assigned according to the
International Union Against Cancer (UICC) and WHO/ISUP
criteria [37]. Median follow-up of the cohort was 71 months (0-
163). The raw data of the tissue microarray have been deposited
under (link will be sent). The Zurich cantonal scientific ethics
committee for pathology (KEK) approved the study and waived
the need for consent (Ref. No. StV-Nr-05/2007).
Immunohistochemistry
The expression of MAGE-C2/CT10 was analyzed immuno-
histochemically as reported recently [20]. Clinical and patholog-
ical parameters of the prostate cancer cases included in the TMA
are summarized in Table S1. Consecutive 3 mm sections were cut
from TMA blocks and mounted on glass slides (Super-Frost Plus,
Menzel, Braunschweig, Germany). For immunohistochemical
staining the Ventana Benchmark automated staining system
(Ventana Medical Systems, Tucson, AZ) and Ventana reagents
were used. After deparaffinization in xylene, slides were rehydrat-
ed in decreasing concentrations of ethanol. Endogenous peroxi-
dase was blocked using Ventana endogenous peroxidase blocking
kit after a rinse with distilled water. For antigen retrieval slides
were heated with cell conditioning solution (CC1, Ventana)
according to manufacturer’s instructions. For the detection of
MAGE-C2/CT-10, the mAb CT10#5 previously generated by
our group [35], for the detection of MAGE-C1/CT7, the clone
CT7-33, DAKO A/S and for NY-ESO-1 the clone E978,
ZYMED were employed and adjusted to the Ventana Benchmark
system after performing titrations (optimal dilution 1:100; 1:80,
1:50 respectively). iVIEW-DAB was used as chromogen. Normal
testicular tissue was chosen as internal positive control for MAGE-
C2/CT10, MAGE-C1/CT7 and NY-ESO-1 expression. MAGE-
C2/CT10 expression was nuclear, MAGE-C1/CT7 and NY-
ESO-1 expression was cytoplasmic and nuclear. For negative
controls, the primary antibody was omitted. Two investigators
(L.v.B., L.K.) performed a blinded evaluation of the slides for
MAGE-C2/CT10, MAGE-C1/CT7 and NY-ESO-1 expression.
Non-interpretable results, due to lack of carcinoma tissue, presence
of necrosis or crush artifact, were excluded from the analysis. At
least 100 cells were counted in each TMA core. Nuclear MAGE-
C2/CT10 immunoreactivity was evaluated using a semi-quanti-
tative, stepwise scoring system: negative (0% of cell nuclei stained);
weak nuclear staining (1–10% of nuclei stained); moderate nuclear
staining (11–50% of nuclei stained); strong nuclear staining (51 to
100% of nuclei stained). Searching for cutoffs in an unbiased way
is a major problem in immunohistochemical studies dealing with a
continuous readout. The median nuclear CT10 immunoreactivity
in prostatectomy cases (median 0%) was chosen as cutoff.
Accordingly, positive nuclear CT10 immunoreactivity was defined
as nuclear staining in at least 1% of target cells. NY-ESO-1- and
CT7- staining is cytoplasmic or nuclear, immunoreactivity was
evaluated using a semi-quantitative, stepwise scoring system:
negative (0% of cells stained); weak nuclear staining (1–10% of
cells stained); moderate staining (11–50% of cells stained); strong
staining (51 to 100% of cells stained). The median NY-ESO-1 and
CT7 immunoreactivity (median 0%) was chosen as cutoff.
Accordingly, positive staining for NY-ESO-1 and CT7 immuno-
reactivity was defined as nuclear or cytoplasmic staining in at least
1% of target cells.
Statistical analyses of tissue microarray data
SPSS version 17.0 (SPSS, Chicago, IL, USA) was used for
statistical analyses. P-values,0.05 were considered significant. In
case of multiple tests the Bonferroni-Holm procedure was applied.
Contingency table analysis and two-sided Fisher’s exact tests were
used to study statistical associations between clinicopathological
and immunohistochemical data. For the comparison of two
Figure 1. Estimation of statistical power versus total sample
size N for different hazard ratios. MAGE-C2/CT10 expression could
be observed in 11 of 341 (3.2%) prostatectomy specimens. The
occurrence of MAGE-C2/CT10 expression should double the risk of
PSA recurrence during follow up, resulting in a hazard ratio of
approximately 2.0. Accordingly, the available sample size of 341
analyzable patients would be sufficient to detect a difference
concerning PSA recurrence with a significance of p,0.05 and a power
of approximately 86%. For higher hazard ratios (2.4, 2.8, 3.2) a statistical
power of approximately 99% was calculated.
doi:10.1371/journal.pone.0021366.g001
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independent samples the non-parametric Mann-Whitney U-test
was calculated. Time to PSA recurrence (cut off$0.1 ng/ml) was
selected as clinical end point. Recurrence-free survival (RFS)
curves were calculated by the Kaplan-Meier method with
significance evaluated by two-sided log-rank statistics. Patients
were censored at the time of their last tumor-free clinical follow-up
visit. Patients not reaching PSA nadir (,0.1 ng/ml) postopera-
tively were excluded. A stepwise multivariable Cox regression
model was adjusted, testing the independent prognostic relevance
of MAGE-C2/CT10 immunoreactivity. The proportionality
assumption for all variables was assessed with log-negative-log
survival distribution functions. Statistical considerations regarding
sample size are given in Figure 1. Calculations were performed
using the respective models of the PASS 2008 software (NCSS,
Kaysville, UT).
Results
MAGE-C2/CT10 expression in normal and malignant
prostate tissue
Comprehensive clinical and histopathologic data are given
in Table S1. In total, 456 of 468 cores (97.4%) could be eva-
luated for MAGE-C2/CT10 immunoreactivity. A representative
MAGE-C2/CT10 staining pattern is shown in Figure 2A–C.
MAGE-C2/CT10 expression was not detected in prostatic
hyperplasia. Organ-confined cancers showed nuclear MAGE-
C2/CT10 expression in 3.3% (11/330) cases, whereas metastatic
and castration resistant disease were positive in 16.3% (7/36) and
17% (5/23) of cases, respectively. Nuclear MAGE-C2/CT10
staining progressively increased from prostatic hyperplasia to
prostate-confined cancer to metastatic and castration resistant
disease (Figure 3; p,0.001). As shown in Figure S1, differential
CT10 expression between normal and neoplastic tissue could be
observed: the percentage of CT10 positivity significantly increased
from benign prostatic hyperplasia to organ confined prostate
cancer to castration resistant prostate and metastatic disease,
including lymph node and bone metastases. As previously de-
scribed [1], neuroendocrine differentiation is more prevalent in
castration resistant prostate cancer. However, no coexpression of
CT10 and neuroendocrine markers such as synaptophysin and
chromogranin could be detected (Figure S2). No correlation
between nuclear MAGE-C2/CT10 expression and age at diag-
nosis, Gleason score, tumor stage, nodal status, surgical margin
status or preoperative PSA levels was found (Table 1). Interest-
ingly, CT10 was significantly co-expressed with other CT antigens
(Fig. 4), like NY-ESO-1 and CT7 (Fig. 2D–I).
Figure 2. Representative immunohistochemical expression patterns from 1–10%, 11–50% and 51–100% of MAGE-C2/CT10 (A, B
and C), MAGE-C1/CT7 (D, E and F) and NY-ESO-1 (G, H and I). A: Radical prostatectomy specimen (Gleason 4+3), B: Bone metastasis of
prostate cancer, C: Bone metastasis of prostate cancer, D: Radical prostatectomy specimen (Gleason 4+3), E: Castration-resistant prostate cancer
(Gleason 5+5), F: Palliative transurethral resection of prostate cancer (Gleason 4+5), G: Bone metastasis of prostate cancer, H: Palliative transurethral
resection of prostate cancer (Gleason 5+4), I: Castration-resistant prostate cancer (Gleason 5+4). Original magnification: 2006; Magnification bar:
20 mM.
doi:10.1371/journal.pone.0021366.g002
Figure 3. Cumulative bar chart representing nuclear immuno-
reactivity for MAGE-C2/CT10 in different prostate tissue types,
showing increased expression from prostatic hyperplasia to
organ-confined prostate cancer to metastatic and castration
resistant disease (p,0.001). BPH: benign prostatic hyperplasia;
ADCA: organ-confined adenocarcinoma of the prostate; MTS: prostate
cancer metastasis; CRPC: castration-resistant prostate cancer.
doi:10.1371/journal.pone.0021366.g003
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MAGE-C2/CT10 and prognosis
Patients with MAGE-C2/CT10 positive prostate cancers were
compared with negative cases regarding RFS by univariate Cox
regression analysis (Table 2). MAGE-C2/CT10 expression was
significantly associated with shorter RFS (p= 0.015; Figure 5).
Patients with MAGE-C2/CT10 positive tumors had a median
RFS of 51 months (95% confidence interval 17-86 months)
compared to 116 months (95% confidence interval 107–125
months) for patients with MAGE-C2/CT10 negative tumors.
Besides the expression of MAGE-C2/CT10, increased Gleason
score (p,0.001), tumor stage (p,0.001), surgical margins (p,
0.001) and preoperative PSA level (p,0.001) were significantly
associated with shorter RFS time.
In a multivariate analysis, a Cox regression model was
developed for assessment of the RFS rate. Characteristics of
variables are shown in Table 3. Only MAGE-C2/CT10 ex-
pression, Gleason score, tumor stage, surgical margin status and
preoperative PSA levels were considered. All variables, including
MAGE-C2/CT10 expression (p = 0.03), remained significant. The
hazard ratio for MAGE-C2/CT10 expression was 2.770 (95%
confidence interval 1.106–6.934).
Discussion
In the present study, we analyzed the presence of MAGE-C2/
CT10 protein in a representative cohort of patients with prostate
cancer and found MAGE-C2/CT10 to be frequently expressed in
advanced prostate cancer; i.e. in metastatic and castration-resis-
tant disease. Moreover, we identified nuclear MAGE-C2/CT10
expression as a predictor of biochemical recurrence after radical
prostatectomy, which was independent of the well established
predictive factors including preoperative PSA, Gleason score,
tumor stage, and surgical margin status.
We detected nuclear MAGE-C2/CT10 positivity in 16.3% and
17% of patients with metastatic and castration resistant disease
respectively, but only in 3.3% of organ confined PCa. This finding
is of clinical significance, because a subgroup of patients with
advanced, castration resistant PCa may be considered for immu-
notherapy in the future. Previous studies have shown that MAGE-
C2/CT10 is able to induce specific immune responses in the auto-
logous host. Cytotoxic T lymphocytes directed against MAGE/
CT-10 epitopes have been found in melanoma patients and
antibodies directed against MAGE-C2/CT-10 were detected in
melanoma and patients [38],[39],[40],[12],[41].
Table 1. Clinicopathological characteristics in relation to
CT10 immunoreactivity in radical prostatectomy tumor
specimens.
Variable Characteristics CT10 immunoreactivity
negative positive p
Age at diagnosis (grouped) ,64 years 143 4 1.000a
$ 64 years 178 6
Gleason score (grouped) 5–6 55 0 0.152b
7 193 6
8–10 80 5
Tumor stage (grouped) pT2a-c 209 6 0.558b
pT3a-b 105 5
pT4 13 0
Nodal status pN0 254 10 1.000a
pN1 17 0
Surgical margin status negative 212 6 0.524a
positive 111 5
Preoperative PSA levels ,10 ng/mL 131 3 0.520a
$ 10 ng/mL 157 7
aFisher’s exact test, two-sided; bold face representing p,0.05.
bPearson Chi-Square, Asymp. Sig., two sided.
p = p-value.
doi:10.1371/journal.pone.0021366.t001
Figure 4. Significant coexpression of MAGE-C2/CT10 with NY-ESO-1 and MAGE-C1/CT7 on the tissue microarray.
doi:10.1371/journal.pone.0021366.g004
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MAGE-C2/CT10 belongs to the MAGE-family of CT antigens
[42]. In a recent study, Yang et al. demonstrated that MAGE-C2
can act as co-repressor of p53 by binding to KAP1 enhancing
suppression of p53. These results suggest that MAGE-C2
contributes to the development of malignancies by providing a
survival advantage [43]. MAGE gene expression is epigenetically
repressed by promoter region methylation in most cells but factors
controlling MAGE gene promoter methylation have not been fully
identified. Yang et al. have shown that MAGE gene expression is
epigenetically controlled by the KIT tyrosine kinase [44].
Understanding the factors controlling MAGE gene expression
may allow more effective therapeutic strategies targeting MAGE
antigens [45],[46],[47].
While our study corroborates previous studies reporting low
incidence of CT antigens in organ-confined prostate cancer, the
increased MAGE-C2/CT10 antigen expression in advanced PCa
was an unexpected novel finding. Also CT antigen expression has
not yet been analyzed in a larger cohort of PCa patients. To our
knowledge, only 30 tumors have been analyzed for MAGE-C2/
CT10 mRNA expression previously: positivity was reported in 1/
10 and 0/20 tumor samples [30],[32]. In other tumors, MAGE-C2/
CT10 protein was previously identified in 34%-48% of hepatocellular
carcinomas [20],[48], in 43% of multiple myeloma [49], in 20% of
high-grade urothelial carcinomas of the urinary bladder [18], in 20%
of head and neck cancers [28], and in 43% of melanomas, res-
pectively. The reported 5% prevalence of MAGE-C2/CT-10
expression in colorectal cancers [50] is comparable to our finding
of rare MAGE-C2/CT-10 expression in primary PCa. A poor
survival was observed in advanced MAGE-C2/CT-10-positive
urothelial carcinoma of the urinary bladder, but MAGE-C2/
CT-10 expression had no prognostic impact in HCC.
Importantly, our study identified MAGE-C2/CT-10 as an
independent predictor of biochemical recurrence after radical
prostatectomy, providing a potential basis for better prognostica-
tion and treatment stratification of patients with PCa. The wide-
spread use of serum prostate-specific antigen (PSA) screening has
led to the identification of an increasing number of asymptomatic
low-stage tumors in younger men [51],[52]. A yet unanswered
important clinical question is if those patients require treatment
and if so, how aggressively should this potential treatment be.
Patients with localized disease are preferentially being treated with
either radical prostatectomy or radiation therapy, both with
curative intent [53],[54]. Currently, prognostication and treatment
stratification at the time of diagnosis are based on clinical stage,
biopsy Gleason grade, and serum PSA levels. In cases treated
by radical prostatectomy, prognosis can be refined by using
pathological stage and Gleason grade. However, these prognostic
indicators do not accurately predict clinical outcome for indivi-
dual patients. Improved markers are needed to determine which
patients are at risk and should therefore be treated more
aggressively. MAGE-C2/CT-10 should be added to the list of
proposed prognostic tumor progression markers, including MUC1
[55], AZGP1 [55], EZH2 [56], E2F3 [57], Ki67 [58],[59], and
CD10 [60].
In conclusion, our data provide evidence that MAGE-C2/CT-
10 may be a candidate for adjuvant and palliative vaccination in a
subset of patients with advanced prostate cancer. In addition,
MAGE-C2/CT-10 expression in early tumor stages indicates a
higher risk for biochemical recurrence after radical prostatectomy.
Supporting Information
Figure S1 Differential CT10 expression between normal and
neoplastic tissue: the percentage of CT10 positivity per tissue
microarray core significantly increased from benign prostatic
hyperplasia to organ confined prostate cancer to castration resis-
tent prostate and metastatic disease, including lymph node and
bone metastases.
(TIF)
Figure 5. Kaplan–Meyer curves regarding disease-free survival
of patients with no MAGE-C2/CT10 expression (blue line)
vs. patients with positive MAGE-C2/CT10 expression (green line)
in invasive prostate carcinomas receiving radical prostatectomy.
doi:10.1371/journal.pone.0021366.g005
Table 3. Multivariate Cox regression analysis.
Variable Characteristics Recurrence-free survival
HR 95% CI p*
Gleason score (grouped) 5–7 vs 8–10 2.237 1.314–3.807 0.003
Tumors stage (grouped) pT2a-c vs pT3a-pT4 1.950 1.184–3.212 0.009
Surgical margin status negative vs positive 2.598 1.599–4.223 ,0.001
Preoperative PSA level ,10 ng/mL vs$10
ng/mL
1.921 1.135–3.252 0.015
CT10 immunoreactivity negative vs positive 2.770 1.106–6.934 0.030
*p-values,0.05 are marked in bold.
HR =Hazard ratio.
doi:10.1371/journal.pone.0021366.t003
Table 2. Univariate Cox regression analysis.
Variable Characteristics Recurrence-free survival
HR 95% CI p*
Age at diagnosis 1.006 0.964–1.050 0.772
Gleason score (grouped) 5–6 vs 7 vs 8–10 2.675 1.831–3.906 ,0.001
Tumors stage (grouped) pT2a–c vs pT3a-4 2.336 1.625–3.356 ,0.001
Surgical margin status negative vs positive 3.268 2.069–5.161 ,0.001
Preoperative PSA level ,10 ng/mL vs$10
ng/mL
2.317 1.432–3.748 0.001
CT10 immunoreactivity negative vs positive 2.913 1.170–7.252 0.022
*P-values,0.05 are marked in bold.
HR =Hazard ratio.
doi:10.1371/journal.pone.0021366.t002
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Figure S2 Whole sections of CT10 positive bone metastasis from
two patients were stained for chromogranin (CRGA) and
synaptophysin, two neuroendokrine markers. No coexpression of
CT10 and neuroendocrine markers could be detected.
(TIF)
Table S1 Clinicopathological characteristics and results of im-
munohistochemistry for patients receiving radical prostatectomy.
(XLS)
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